DexCom, Inc.

DexCom, Inc. is a medical device company specializing in continuous glucose monitoring (CGM) systems for people with diabetes. Its flagship product, the Dexcom G6 and G7, provide real-time glucose readings without the need for fingerstick calibration, helping patients manage their condition more effectively. The company also offers integrated systems for insulin pumps and digital health platforms.

DexCom generates revenue primarily from the sale of CGM sensors, transmitters, and receivers. Its business model is recurring: sensors are disposable and replaced every 10 days, creating a steady stream of consumable sales. The company also earns from software subscriptions and data analytics services. Revenue is predominantly from the US, with growing international expansion.

DexCom operates in the highly competitive medical devices sector, specifically the diabetes management market. It competes with Abbott Laboratories (FreeStyle Libre) and Medtronic (Guardian). DexCom is positioned as a premium, high-accuracy CGM provider, often preferred by type 1 diabetes patients and those on insulin pumps. Its strong brand and continuous innovation help maintain a leading market share.

DexCom's primary customers are people with diabetes (both type 1 and type 2) who require insulin therapy. Its products are prescribed by endocrinologists and primary care physicians. The main geographic market is the United States, which accounts for the majority of sales, followed by Europe and other international regions. The company also targets healthcare systems and payers for reimbursement coverage.

An auto-generated descriptive profile based on company data, for informational purposes only.